Exclusive Summary

• - As of 2024 there are no FDA‑approved generics and no EMA centralized approval, leaving white‑space for first‑to‑market distribution in multiple regions.
• - Global CML prevalence is ~0.6–0.8 million, with ~5–10% failing or intolerant to ≥2 TKIs (≈30,000–80,000 patients) who need a non‑TKI mechanism.
• - Clinical data show CHR ~60–70% and cytogenetic responses ~15–20% in chronic phase, with activity against T315I and multi‑TKI resistance.
• - As a parenteral solution, many regulators allow in‑vivo BE waivers with Q1/Q2 sameness and ICH‑CTD filings; the 1 mg/1 mL SC format fits outpatient use and lean logistics.
• - Versus originator, a 30–70% price reduction is achievable, cutting per‑cycle and overall treatment costs and improving payer uptake.